These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 10743240)

  • 1. [Prethrombotic state in patients with chronic obstructive pulmonary disease and treatment with heparin].
    Xie M; Wang Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1998 Dec; 29(4):411-4. PubMed ID: 10743240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group.
    Alessandri C; Basili S; Violi F; Ferroni P; Gazzaniga PP; Cordova C
    Thromb Haemost; 1994 Sep; 72(3):343-6. PubMed ID: 7855781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease.
    Ferroni P; Basili S; Martini F; Vieri M; Labbadia G; Cordova C; Alessandri C; Gazzaniga PP
    J Investig Med; 2000 Jan; 48(1):21-7. PubMed ID: 10695266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients.
    Polosa R; Malerba M; Cacciola RR; Morjaria JB; Maugeri C; Prosperini G; Gullo R; Spicuzza L; Radaeli A; Di Maria GU
    Intern Emerg Med; 2013 Oct; 8(7):567-74. PubMed ID: 21660493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The study on prethrombotic state in patients with chronic obstructive pulmonary disease and cor pulmonale].
    Ma D
    Zhonghua Jie He He Hu Xi Za Zhi; 1993 Feb; 16(2):95-7, 124. PubMed ID: 8221962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Is the assessment of prothrombin fragment F1+2 for monitoring of heparin therapy in patients with deep vein thrombosis useful?].
    Korte W; Corbetta C; Schmid L
    Schweiz Med Wochenschr; 1995 Mar; 125(9):420-3. PubMed ID: 7892570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal time to use low molecular weight heparin on prethrombotic state of rat chronic obstructive pulmonary disease model.
    Wang Y; Sun N; Cheng Z; Tong L
    Chin Med J (Engl); 2014; 127(3):518-21. PubMed ID: 24451960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of hypercoagulable state in patients with malignancies by using prothrombin fragment F1 + 2].
    Nakagawa K; Tsuji H; Yamada K; Yamada Y; Masuda H; Yamagami M; Yoneda M; Takada O; Sawada S; Kitani T
    Rinsho Ketsueki; 1992 Nov; 33(11):1666-72. PubMed ID: 1469781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism.
    Kyrle PA; Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Melichart M; Traxler G; Weltermann A; Speiser W; Lechner K
    Thromb Haemost; 1997 May; 77(5):829-33. PubMed ID: 9184387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipidemias and fibrinolysis.
    Puccetti L; Bruni F; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Auteri A
    Ital Heart J; 2002 Oct; 3(10):579-86. PubMed ID: 12478815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Markers of hemostatic system activation in pulmonary embolism. Changes during and after cessation of anticoagulant treatment.
    de Raucourt E; Meyer G; Landais P; Gouaref Z; Morinet P; Monge F; Sors H; Fischer AM
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):249-53. PubMed ID: 10870805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic clotting activation by low-grade endotoxaemia in liver cirrhosis: a potential role for endothelial procoagulant activation.
    Ferro D; Basili S; Lattuada A; Mantovani B; Bellomo A; Mannucci PM; Violi F
    Ital J Gastroenterol Hepatol; 1997 Oct; 29(5):434-40. PubMed ID: 9494853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.
    Schutgens RE; Esseboom EU; Snijder RJ; Haas FJ; Verzijlbergen F; Nieuwenhuis HK; Lisman T; Biesma DH
    J Lab Clin Med; 2004 Aug; 144(2):100-7. PubMed ID: 15322504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of heparin responses in arterial and venous thromboembolism using molecular markers for thrombosis.
    Sobel M; Sternbergh WC; Marques D; Grimsdale AS
    Circulation; 1993 Nov; 88(5 Pt 2):II426-31. PubMed ID: 8222189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The significance of maximal expiratory concentrations of CO2 (MEC CO2) in the negative diagnosis of acute pulmonary embolism in chronic obstructive bronchopneumopathies].
    Grosbois JM; Bart F; Douay B; Fortin F; Dernis JM; Wallaert B
    Rev Mal Respir; 1995; 12(1):35-41. PubMed ID: 7899665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. The DVTENOX Study Group.
    Thromb Haemost; 1993 Dec; 70(6):909-14. PubMed ID: 8165610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemostatic and lipid determinants of prothrombin fragment F1.2 and D-dimer in plasma.
    MacCallum PK; Cooper JA; Martin J; Howarth DJ; Meade TW; Miller GJ
    Thromb Haemost; 2000 Mar; 83(3):421-6. PubMed ID: 10744148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation.
    Fu R; Wu S; Wu P; Qiu J
    Europace; 2011 Jan; 13(1):31-6. PubMed ID: 20852292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicentric evaluation of a new assay for prothrombin fragment F1+2 determination.
    Bruhn HD; Conard J; Mannucci M; Monteagudo J; Pelzer H; Reverter JC; Samama M; Tripodi A; Wagner C
    Thromb Haemost; 1992 Oct; 68(4):413-7. PubMed ID: 1448772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.